120 related articles for article (PubMed ID: 29317067)
41. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
Perez RG; Hastings TG
J Neurochem; 2004 Jun; 89(6):1318-24. PubMed ID: 15189334
[TBL] [Abstract][Full Text] [Related]
42. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
43. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
[TBL] [Abstract][Full Text] [Related]
44. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration.
Frank-Cannon TC; Tran T; Ruhn KA; Martinez TN; Hong J; Marvin M; Hartley M; Treviño I; O'Brien DE; Casey B; Goldberg MS; Tansey MG
J Neurosci; 2008 Oct; 28(43):10825-34. PubMed ID: 18945890
[TBL] [Abstract][Full Text] [Related]
45. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
46. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
47. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
Kovacs GG; Milenkovic IJ; Preusser M; Budka H
Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
[TBL] [Abstract][Full Text] [Related]
48. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
49. Nigral dopaminergic cell loss in vitamin E deficient rats.
Dexter DT; Nanayakkara I; Goss-Sampson MA; Muller DP; Harding AE; Marsden CD; Jenner P
Neuroreport; 1994 Sep; 5(14):1773-6. PubMed ID: 7827329
[TBL] [Abstract][Full Text] [Related]
50. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
[TBL] [Abstract][Full Text] [Related]
51. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
Korecka JA; Eggers R; Swaab DF; Bossers K; Verhaagen J
Restor Neurol Neurosci; 2013; 31(2):155-67. PubMed ID: 23271419
[TBL] [Abstract][Full Text] [Related]
52. Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease.
Hornykiewicz O; Shannak K
J Neural Transm Suppl; 1994; 42():219-27. PubMed ID: 7964689
[TBL] [Abstract][Full Text] [Related]
53. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
54. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
[TBL] [Abstract][Full Text] [Related]
55. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?
Barzilai A; Melamed E; Shirvan A
Cell Mol Neurobiol; 2001 Jun; 21(3):215-35. PubMed ID: 11569535
[TBL] [Abstract][Full Text] [Related]
56. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y
Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040
[TBL] [Abstract][Full Text] [Related]
57. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
58. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
59. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
Lo Bianco C; Déglon N; Pralong W; Aebischer P
Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
[TBL] [Abstract][Full Text] [Related]
60. New insights into the cause of Parkinson's disease.
Jenner P; Schapira AH; Marsden CD
Neurology; 1992 Dec; 42(12):2241-50. PubMed ID: 1461374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]